Kornimate/medical-research-clean huggingface dataset:
biomechanical and morphological changes in dystrophic muscle

Conditions: Duchenne Dystrophy Muscular

Summary: the loss of ability to walk in many children with dmd (duchenne muscular dystrophy) is a pejorative event. biomechanical and morphological unknowledge about the loss of the walk ability in children with dmd is an obstacle in reeducative, pharmacological or surgical therapeutic targets.

the loss of ability to walk in many children with dmd (duchenne muscular dystrophy) is a pejorative event. biomechanical and morphological unknowledge about the loss of the walk ability in children with dmd is an obstacle in reeducative, pharmacological or surgical therapeutic targets. we suppose that there are muscular characteristics and predictive parameters of the loss of walk ability. the identification of these potential therapeutic targets would improve the surveillance and the clinical care but would also guide future clinical and fundamental trials too.

Eligibility criteria:
inclusion criteria: * young man ou woman (5 to 17 years old) with duchenne muscular dystrophy (confirmed by immunohistochimy on the muscular biopsy and/or mutation in the dystrophin confirmed by molecular biology) * time more than 7 secondes to test of 10 m and/or distance less than 330 m to walk test of 6 minutes. these values are recent markers to include children with a strong risk of loss of walking ability in 2 years. * parental inform sign consent and / or child inform consent exclusion criteria: * recent orthopaedic surgery of lower limbs (6 months) * other chronic disease associated, which have an impact on the walking * cognitive deficiency or behavior disorders limiting the understanding of the study * children who can benefit atu (translarna ® or other) during the study * all mri contradications : pacemaker or neurosensory stimulator or implantable defibrillator, neurosurgical valves, cochlear implant or ferromagnetic implants near nervous structures, brace, metallic prostheses, not cooperative or agitated patients, patient claustrophobic, pregnant woman.

Keywords: dmd morphological predictive factors mechanical
remote oximeter monitoring post-discharge to reduce emergency room visits and rehospitalization

Conditions: Emergencies

Summary: this randomized clinical trial will determine the efficacy of remote patient monitoring using an owlet oss 3.0 pulse oximeter for the reduction of emergency room visits and high-acuity rehospitalizations among high-risk infants after nicu discharge.

to determine if among infants being discharged from the neonatal intensive care unit (nicu) without a cardiorespiratory monitor or respiratory support, remote patient monitoring using an owlet oss 3.0 pulse oximeter (owlet, lehi, ut) decreases emergency room visits and high-acuity rehospitalizations after discharge compared with routine care. infants being discharged from the neonatal intensive care unit (nicu) without a cardiorespiratory monitor or respiratory support are eligible for inclusion. the investigators will provide remote patient monitoring using an owlet oss 3.0 pulse oximeter to infants in the intervention group for a 6 month period. the investigators will collect monthly outcome measures from caregivers of all infants.

Eligibility criteria:
inclusion criteria: * infants being discharged from the nicu * off all respiratory support (oxygen, cpap, ventilator) before discharge home * gestational age ≥ 22 0/7 weeks' gestation at birth * parents/legal guardians have provided consent for enrollment exclusion criteria: * a major malformation, a neuromuscular condition that affects respiration or causes apnea, complex congenital heart disease and hemodynamically significant shunts, or terminal illness or decision to withhold or limit support. * infants being discharged from the neonatal intensive care unit (nicu) with a cardiorespiratory monitor or respiratory support are not eligible for inclusion.
transanal tube drainage in endoscopic submucosal dissection of the colorectal tumor

Conditions: Colorectal Tumor

Summary: we design the clincal trial to investigate the efficacy of transanal tube drainage in colorectal esd.

endoscopic submucosal dissection (esd) is a technique for endoscopic tissue resection that enables endoscopists to control the depth and direction of diathermic knife incisions.recently, the number of reports in which esd has been successfully used to treat colorectal tumors has increased. but the complatios with colorectal esd were higher than esophagus and stomach esd.we design the clincal trial to investigate the efficacy of transanal tube drainage in colorectal esd.

Eligibility criteria:
inclusion criteria: * endoscopy proven colorectal polyp\>2cm, lst\>3cm, smts\<2cm suitable for esd no other organic disease of colorectal removing a single lesion one time informed consent exclusion criteria: * complicated other colorectal diseases, such as,crohn's disease familial adenomatous polyposis with previous colorectal surgery pregnancy or lactation absolute contraindications to general anesthesia or prolonged pneumoperitoneum (asa class \> iii) esd conversion to laparotomy patients cannot receive esd patients and/or family members can not understand and accept this study

Keywords: esd;transanal tube drainage;colorectal tumor
correlation between the lower extremities and lumbar degenerative diseases of the elderly

Conditions: Lumbar Osteoarthritis

Summary: the study has before mentioned the concept of "knee - spine syndrome" domestically, on the basement of which, the new study intends to perform another further study on the relationship between lumbar and lower extremity degenerative diseases.

a prosepective, single-center, factorial design, randomized study will be performed. in this study, the 120 participants with degenerative lumbar and knees disease coped with the standard were included, then were assigned into 4 groups randomly. the patients in 3 operation groups were treated with posterior lumbar interbody fusion(plif or plf) or total knee arthroplasty (tka) or both of them in one stage respectively and the forth group with no surgery. the comparison between observation and operation group and the difference on self-control pre-and post-operatively in operation group within 6 months were measured and valuated. the result will be formed by the correlation and causal relationship on sagittal parameters on photograph, biomechanics, neuroelectrophysiology and molecular biology and the conclusions drawn by the use of modern medical basic research methods will formulate the treatment principles on it.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed lss need to be underwent plif or plf 2. and patients who need surgery and are limited by knee extension greater than 10 ° 3. ineffective conservative treatment for 6 months 4. patients have never relevant surgery before 5. participants will be volunteered randomly assigned to surgery group and observation group. exclusion criteria: 1. people have had similar lumbar or knee surgery 2. patients with lumbar or knee joint tumor or congenital malformation 3. there are contraindications of surgery such as infections and serious illness.

Keywords: knee - spine syndrome plif tka sagittal parameters neuroelectrophysiology
gilterinf 2022 study (gilteritinib related infections)

Conditions: Acute Myeloid Leukemia

Summary: the study is observational, retrospective-prospective, multicenter "real-life" study involving 26 centers belonging to the seifem group. the goal of this study is to obtain a real-life experience in the management and outcome of infectious issues of patients with relapsed/resistant acute myeloid leukemia who receive gilteritinib therapy, given that recent approval of this drug.

the study is observational, retrospective-prospective, multicenter "real-life" study. regarding the retrospective part, clinical data will be collected on all patients with acute myeloid leukemia flt3+ treated with gilteritinib from when the drug was approved and marketed in italy (april 2, 2020) until april 30, 2022. enrollment in the prospective cohort will have an estimated duration of 24 months from the time of study approval. patients enrolled in the last month will be followed for six months from the date of enrollment to check for the occurrence of any infections. for each case of a patient receiving salvage monotherapy with gilteritinib, a control patient with relapsed/refractory flt3+ acute myeloid leukemia on salvage chemotherapy should also be included.

Eligibility criteria:
inclusion criteria: population * all patients with flt3+ relapsed/refractory aml to any line of therapy treated with gilteritinib * patients ≥18 years of age * signature of appropriate informed consent exclusion criteria: - patients \< 18 years old

Keywords: relapsed/refractory acute myeloid leukemia flt3+ flt3 inhibitors gilteritinib infections
the healthy baby bottoms study

Conditions: Diaper Dermatitis

Summary: diaper dermatitis is one of the most common dermatologic diseases affecting infants and children. the incidence is highest among those 9-12 months old and it has been reported to affect 7-50% of infants in the us. it is caused by skin exposure to a combination of several factors including: excessive moisture, topical irritants, reduced ph, friction, maceration and bacterial infection. when infants soil their diaper, diaper contents saturate the area raising the ph of the skin above the normal level of 5 or less, and leaving the area highly vulnerable to maceration from friction. irritants in urine and feces are then able to penetrate the macerated skin, causing inflammation and greater skin friability. an elevation in the skin ph allows pathogenic bacteria to overgrow, and combined with the breakdown in the skin's outer epithelial barrier, can lead to bacterial infection. theraworx foam formulation-allantoin liquid by avadim technologies, inc. is a skin protectant with use for temporary protection of minor cuts, scrapes, burns and chapped or cracked skin. as such, theraworx foam used in the diaper area may be beneficial for protecting skin against diaper rash wounds, as well as for assisting with wound healing and reducing any associated pain. the purpose of this study is to determine caregivers' perceptions of the benefits of using theraworx foam on their infant's diaper area as part of their hygienic routine, including whether they feel the product is pleasant and easy to use, and whether they feel it helps prevent and reduce the severity of diaper dermatitis in their infants 1-14 months old.


Eligibility criteria:
inclusion criteria: * read english at the 8th grade level * have reliable access to email for 7 weeks * complete the first online survey within 24 hours of the request * custodial guardian of an infant between the ages of 1-12 months old living with him/her, wearing diapers, and has had ≥1 diaper rash in the 2 months preceding recruitment exclusion criteria: * does not have a stable address at which to receive a package of theraworx and is unable/unwilling to pick it up at children's national health system * infant is immunocompromised, has a congenital disorder, or on the day of recruitment, has a diaper rash, has a moderate to severe illness requiring hospitalization or transfer to the emergency room, or was circumcised \<10 days prior.
the applicability of different scoring systems and use of steroids in the treatment of hospital acquired pneumonia

Conditions: Pneumonia Hospital Acquired

Summary: cross sectional randomized clinical trial study will be done at respiratory intensive care unit and chest department at assiut university hospitals on all patients who developed hospital acquired pneumonia including ventilator associated pneumonia through two years duration to assess the prognostic value of different severity scores including (psi, curb65, smart cop, idsa/ats and soar) in patients with hap, assess platelet count as a marker for severity, evaluate efficacy and safety of adjuvant systemic steroids in patients with severe conditions and measurement of cortisol level to assess steroid response before administration.

the following parameters will be recorded: * demographic data: including age, sex, smoking history. * clinical data: glasgow coma scales, co-morbidities are determined by reviewing the patients' clinical histories, chest examination. * vital signs: including body temperature, respiratory rate, heart rate, and arterial blood pressure. * oxygenation data: including arterial blood gases in fixed days (at the start, 3rd day and 7th day of steroid administration), ratio of partial oxygen tension in arterial blood to fraction of inspired oxygen (pao2/fio2 ratio). * laboratory data include complete blood picture focusing on leukocytic count and platelets, kidney and liver function tests, serum electrolytes, erythrocyte sedimentation rate, c reactive protein, sputum culture and cortisol level before steroid administration. * radiology data include chest x-ray and chest ultrasonography at the day of diagnosis and at 7th day of steroid administration. chest ct will be done if possible. procedures: systemic steroids will be administered early with a dosages equivalent to prednisone 40 mg/day for 7 days which is considered as a "stress dose" of systemic corticosteroids for pneumonia. the patients will also receive the appropriate initial intravenous antibiotic medication and the standard care as recommended in ricu policy. cortisol level will be measured before steroid administration.

Eligibility criteria:
inclusion criteria: this study will be conducted on admitted patients aged ≥18 years that developed hospital acquired pneumonia including ventilator associated pneumonia. its diagnosis is confirmed by developing pneumonia after 48 h of admission and they had new or progressive infiltrates on the chest x-ray with one of the 3 requirements of: fever more than 37.8 c or purulent sputum or leukocytosis. exclusion criteria: 1. patients having lung cancer and those who hadn't the full data for scoring fulfilled. 2. chronically immunosuppressed patients (chemotherapy, human immunodeficiency virus infection, or other immunosuppressive agents). 3. condition requiring prolonged steroid use \> 0.5 mg/kg/day of prednisone equivalent. 4. major gastrointestinal bleeding within 3 months. 5. patients with prolonged intubation and having tracheostomy. 6. patients with neurological disorders or encephalopathy. 7. patients with pandemic h1n1 influenza a pneumonia.
hemodynamic assessment of the right ventricle using pressure-volume loop catheter and pulmonary artery catheter in patients undergoing left ventricular assist device placement

Conditions: Right Ventricular Dysfunction

Summary: this study will include the placement of a pressure volume (pv) loop catheter in the right atrium of patients undergoing left ventricular assist device (lvad) placement and measure relevant pv loop data. transesophageal echocardiography (tee) and pulmonary artery (pa) catheter parameters as comparators to the pv loop will be recorded.

this will be a prospective observational study design to characterize right ventricular function in 5 consecutive patients undergoing lvad implantation at the university of minnesota medical center (ummc). pre-, intra- and postoperative care delivery to all enrolled and consented patients will meet the standards of care otherwise delivered to patients undergoing lvad implantation at ummc; care delivery will be at the discretion of the clinical care team and will not be altered based on the output of the right ventricular high-fidelity conductance catheters.

Eligibility criteria:
inclusion criteria: - patients undergoing left ventricular assist device (lvad) placement at the university of minnesota medical center exclusion criteria: * patients with a history of internal jugular vein thrombosis or known reasons for not being able to thread a central venous catheter through either internal jugular vein * patients with a history of known esophageal strictures, esophageal or stomach cancer, esophageal varices, or any patient in whom a tee is contraindicated * patients with permanent pacemakers whose right ventricle is being paced and not in normal sinus rhythm * patients unable to consent to participating in the study * patients who are pregnant will be excluded, as part of standard care, all female patients are screened for pregnancy prior to surgery.
assessment of lipid profile in juvenile systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: . to determine pattern and frequency of dyslipoproteinemia in patients with newly diagnosed juvenile sle and to assess effect of disease activity on lipid profile of patients with juvenile sle.

systemic lupus erythematosus (sle) is a chronic autoimmune disease characterized by multisystem inflammation and the presence of circulating autoantibodies against self-antigens leading to inflammatory damage of many target organs including the skin, joints, kidneys, blood cells, blood vessels, and the central nervous system.premature atherosclerosis has been recognized as an important issue for patients with sle since the mid-1970s. among the traditional risk factors of atherosclerosis, a history of smoking, diabetes, hypertension, and abnormal lipid profile have been shown to be important (7). in patients with juvenile sle, smoking, diabetes, and uncontrolled hypertension are not common and therefore abnormal lipid profiles may be the most important risk factor.the lipid profile of both children and adults with sle is the result of a combination of the influences of active disease, therapies, and genetics. the best way to determine the maximal potential effect of disease activity itself would be to examine patients at the time of presentation of sle, when they are likely to have high disease activity but no effect of corticosteroid therapy.studies in patients with active sle suggested that there is a distinct pattern of lipid abnormalities of increased very low-density lipoprotein (vldl) and triglycerides and decreased high-density lipoprotein (hdl-c), cholesterol and apolipoprotein a1 levels ("active sle pattern")

Eligibility criteria:
inclusion criteria: 1. patients who are diagnosed according to 2019 european league against rheumatism (eular) /american college of rheumatology (acr) sle classification criteria . 2. patients diagnosed with jsle between 5 and 18 years of age exclusion criteria: * 1. patients on lipid lowering drugs for any other reason. 2. patients with other autoimmune disease.
interest of intravitreal injections of anti-vegf as initial and adjuvant treatment in coats disease

Conditions: Retinal Telangiectasis; Coats Disease

Summary: coats disease is a predominantly unilateral progressive retinal vascular disease, characterized by retinal telangiectasias with intra- or subretinal exudate deposits, which can lead to retinal detachment and one-sided blindness. several treatment modalities are available and the choice of one of them depends on the stage of the disease and the habits of each center (laser photocoagulation, cryotherapy ...). vegf (vascular endothelial growth factor) was found to be significantly elevated in the aqueous humor and subretinal fluid of patients with coats disease. several studies have shown the potential efficacy of intra-vitreous injections of anti-vegf. but the results on their effectiveness have been evaluated only on small series of patients. most published studies have analyzed their efficacy combined with another treatment, mainly laser photocoagulation. the true efficacy of anti-vegf therapy as initial therapy, and then combined in coats disease remains unknown. currently, several centers are initiating first-line anti-vegf injections, although no rigorous evaluation of this therapeutic strategy has been conducted. the identification of the best treatment regimen will allow in the future the reduction of laser reprocessing and will ensure a better functional benefit in the affected patients.


Eligibility criteria:
inclusion criteria: * coats disease confirmed by fundus examination and fluorescein angiography * stage 2 or 3 at the fundus (shields classification) * naive to any eye treatment on the eye affected by coats disease exclusion criteria: * other ocular pathology on the eye affected by coats' disease * bilateral forms of the disease * history of hypersensitivity to bevacizumab * history of hypersensitivity to products of chinese hamster ovary cells or other recombinant human or humanized antibodies * allergic reaction in a previous fluorescein retinal angiogram * pregnancy or breastfeeding * active or suspected periocular infection * contraindication to treatments used for general anesthesia and morphine derivatives * cardiovascular, haemorrhagic and gastrointestinal risks * premature baby who has not reached the correct age of 37 weeks

Keywords: retinal telangiectasis coats disease anti-vegf (vascular endothelial growth factor)
shear wave elastography of rectal adenomas and cancer

Conditions: Rectal Neoplasms; Elasticity Imaging Techniques

Summary: the diagnosis of rectal lesions is a challenging task, and the accuracy of the primary staging is important preoperatively. a relatively novel technology makes it possible to measure the tissue stiffness during endorectal ultrasonography. the purpose of this study is to evaluate the diagnostic value of shear wave elastography (swe). the hypothesis is that the tissue stiffness is higher in malignant tissue than in benign lesions.

this study will include patients with an endoscopy verified rectal lesion referred to the radiology department for pretreatment evaluation. during the investigation, patients will undergo magnetic resonance imaging (mri) and endorectal ultrasonography (erus). during the erus, the tissue stiffness of the lesion and visible lymph nodes will be measured using the swe technology. hypotheses: 1. tumour stiffness measurement by swe gives a statistically significantly higher value in malignant processes than in benign rectal tumors. 2. tissue stiffness measurement with swe gives a statistically significantly higher value in lymph node metastases than in reactive enlarged lymph nodes. 3. there is a statistically significant correlation between swe and mri apparent diffusion coefficient (adc) histopathology report of surgical specimen will serve as endpoint.

Eligibility criteria:
inclusion criteria: * adults above 18 years of age * rectal lesions discovered during endoscopy * lesions located no more than 15 cm above the anal verge exclusion criteria: * non-eligibility for mri (e.g. claustrophobia, implants) * preoperative radiotherapy and/or chemotherapy
a 4-week study of the safety, efficacy, and pharmacokinetics of jzp-110 [(r)-2-amino-3-phenylpropylcarbamate hydrochloride] in subjects with parkinson's disease and excessive sleepiness

Conditions: Excessive Sleepiness; Parkinson Disease

Summary: this study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and pk of jzp-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic pd.


Eligibility criteria:
inclusion criteria: 1. diagnosis of idiopathic pd according to the uk pds brain bank criteria. 2. hoehn and yahr stage 1, 2, or 3. 3. screening and baseline ess scores \>11. exclusion criteria: 1. diagnosis of other degenerative parkinsonian syndromes (e.g., progressive supranuclear palsy, multiple system atrophy \[msa\], or dementia with lewy bodies \[dlb\]). 2. usual nightly time in bed of \<6 hours, including the night before the baseline visit. 3. untreated or inadequately treated moderate to severe osa. 4. has evidence at screening of severe cognitive impairment or has cognitive impairment that in the opinion of the investigator would prevent completion of study procedures or the ability to provide informed consent.